ABSTRACT
BACKGROUND Gut microbiota have been implicated in atherosclerotic disease, but their relation with subclinical coronary atherosclerosis is unclear. This study aimed to identify associations between the gut microbiome and computed tomography-based measures of coronary atherosclerosis, and to explore relevant clinical correlates.
METHODS We conducted a cross-sectional study of 8973 participants aged 50 to 65 without overt atherosclerotic disease from the population-based Swedish Cardiopulmonary BioImage Study (SCAPIS). Coronary atherosclerosis was measured using coronary artery calcium score (CACS) and coronary computed tomography angiography (CCTA). Gut microbiota species abundance and functional potential were assessed with shotgun metagenomics sequencing of stool samples, and their association with coronary atherosclerosis was evaluated with multivariable regression models adjusted for cardiovascular risk factors. Associated species were evaluated for association with inflammatory markers, metabolites, and corresponding species in saliva.
RESULTS The mean age of the study sample was 57.4 years, and 53.7% were female. Coronary artery calcification was detected in 40.3% of participants, and 5.4% had at least one stenosis with more than 50% occlusion. Sixty-four species were associated with CACS independent of cardiovascular risk factors, with the strongest associations observed for Streptococcus anginosus and S. oralis subsp. oralis (P<1×10-5). Associations were largely similar across CCTA-based measurements. Out of the 64 species, 19 species, including streptococci and other species commonly found in the oral cavity, were associated with high-sensitivity C-reactive protein plasma concentrations and 16 with neutrophil counts. Oral species in the gut were negatively associated with plasma indole propionate and positively associated with plasma secondary bile acids and imidazole propionate. Five species correlated with the same species in saliva and were associated with worse dental health in the Malmö Offspring Dental Study. Microbial functional potential of dissimilatory nitrate reduction, anaerobic fatty acid beta-oxidation and amino acid degradation was associated with CACS.
CONCLUSIONS This study provides evidence of an association of a gut microbiota composition characterized by increased abundance of Streptococcus spp. and other species commonly found in the oral cavity with coronary atherosclerosis and systemic inflammation. Further longitudinal and experimental studies are warranted to explore the potential implication of a bacterial component in atherogenesis.
WHAT IS NEW?
Shotgun metagenomics identified associations between gut species and subclinical atherosclerosis assessed with computed tomography-derived coronary artery calcium score (CACS) in 8973 participants, with an overrepresentation of the Streptococcus and Oscillobacter genera.
The relative abundance of CACS-associated oral species detected in fecal samples was negatively associated with indole propionate, while positively associated with secondary bile acids and imidazole propionate.
Gut Streptococcus spp. were positively associated with circulating biomarkers of systemic inflammation and infection response, and with the same species located in the mouth, which were in turn associated with oral pathologies.
WHAT ARE THE CLINICAL IMPLICATIONS?
We describe the link between gut microbiota composition, especially species commonly found in the mouth, with subclinical coronary atherosclerosis and biomarkers of inflammation in the largest cardiovascular and metagenomics study to date.
The effects of gut and oral Streptococcus spp. on risk for coronary artery disease merit further longitudinal and experimental studies.
Competing Interest Statement
The authors declare the following competing interests: Ms Pita, Ms Nielsen, Drs Eklund, Holm, and Nielsen are employees of Clinical Microbiomics A/S, where samples were processed and DNA extraction and estimations of relative abundance of the metagenomics species were done. Dr Ärnlöv has received lecture fees from Novartis and AstraZeneca and has served on advisory boards for AstraZeneca and Boerhinger Ingelheim, all unrelated to the present paper. Dr Nilsson has received lecture fees from Novartis, Novo Nordisk, Amgen, and Boerhinger Ingelheim. The other authors declare no competing interests.
Funding Statement
The main financial support for the study was from the European Research Council [ERC-2018-STG-801965 (T.F.), ERC-CoG-2014-649021 (M.O.-M.), and ERC-STG-2015-679242 (J.G.S.)]. Funding was also provided by the Swedish Research Council [VR, 2019-01471 (T.F.), 2018-02784 (M.O.-M.), 2018-02837 (M.O.-M.), 2019-01015 (J.Ä.), 2020-00243 (J.Ä.), 2019-01236 (G.E.), 2017-02554 (J.G.S.), 2022-01460 (SA) and EXODIAB 2009-1039 (M.O.-M.)]; the Swedish Heart-Lung Foundation [Hjärt-Lungfonden 20190505 (T.F.), 20200711 (M.O.-M.), 20180343 (J.Ä.), 2019-0526 (J.G.S.), 20200173 (G.E.)]; the A.L.F. governmental grant [2018-0148 (M.O.-M.)]; the Novo Nordisk Foundation [NNF20OC0063886 (M.O.-M.)]; the Swedish Diabetes Foundation [(DIA 2018-375 (M.O.-M.)]; the Swedish Foundation for Strategic Research [LUDC-IRC 15-0067 (M.O.-M.)]; Formas [2020-00989 (S.A.)]; Göran Gustafsson Foundation [2016 (T.F.)]; and Axel and Signe Lagerman's Foundation (T.F.). The Swedish CArdioPulmonary bioImage Study (SCAPIS) was funded mainly by the Swedish Heart-Lung Foundation. The study was also funded by the Knut and Alice Wallenberg Foundation, the Swedish Research Council and VINNOVA (Sweden's innovation agency), the University of Gothenburg and Sahlgrenska University Hospital, Karolinska Institutet and Stockholm County Council, Linköping University and University Hospital, Lund University and Skåne University Hospital, Umeå University and University Hospital, and Uppsala University and University Hospital. The Malmö Offspring Dental Study (MODS) was funded mainly by Oral Health Related Research by Region Skåne (OFRS 422361, OFRS 512951, OFRS 567711, OFRS 655561, OFRS 752071, OFRS 853031, OFRS 931171, and OFRS968144). The Malmö Offspring Study (MOS) was funded by the Research Council of Sweden [VR 521-2013-2756 (P.M.N.)], the Swedish Heart and Lung Foundation [Hjärt-Lungfonden 20150427 (P.M.N.)], and by A.L.F. from the local Region Skåne County Council (P.M.N.). In addition, funding was obtained from Ernhold Lundströms Stiftelse (L.B.). The computations and data handling were enabled by resources in project sens2019512 provided by the National Academic Infrastructure for Supercomputing in Sweden (NAISS) and the Swedish National Infrastructure for Computing (SNIC) at Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) partially funded by the Swedish Research Council through grant agreements no. 2022-06725 and no. 2018-05973.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants gave written informed consent. The study was conducted in accordance with the Declaration of Helsinki and was approved by the regional ethics committees (SCAPIS: Dnr 2010-228-31M and Dnr 2018/315; MODS: Dnr 2013/761; and MOS: Dnr 2012/594).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Shared first authorship
↵† Shared senior authorship
1. Analysis accounting for interrelatedness of individuals by mixed models with family as a random intercept 2. New analysis of individual associations between gut metabolic modules and coronary artery calcium score, instead of the enrichment analysis 3. New analysis of individual associations between plasma metabolites and species obtained from the GUTSY Atlas (https://gutsyatlas.serve.scilifelab.se/), instead of the enrichment analysis.
Data Availability
De-identified metagenomic sequencing data can be accessed from the ENA under accession number PRJEB51353 (https://www.ebi.ac.uk/ena/browser/view/prjeb51353). Access to the pseudonymized data requires ethical approval from the Swedish Ethical Review Board and approval from the SCAPIS Data access board (https://www.scapis.org/data-access/).
Non-standard Abbreviation and Acronyms
- CACS
- Coronary artery calcium score
- CCTA
- Coronary computed tomography angiography
- CVD
- Cardiovascular disease
- GMM
- Gut metabolic module
- hsCRP
- High-sensitivity C-reactive protein
- ln
- Natural logarithm
- MGS
- Metagenomics species
- MODS
- Malmö Offspring Dental Study
- MOS
- Malmö Offspring Study
- SCAPIS
- Swedish CArdioPulmonary bioImage Study
- SIS
- Segment involvement score
- VGS
- Viridans streptococci group
